Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
NET LOSS $ (80,030) $ (963,896)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 43,320 43,472
Equity-based compensation 2,008 15,427
Goodwill impairment 0 851,456
Amortization of original issue discount and debt issuance costs 340 0
Accretion of contingent consideration 113 188
Mark-to-market adjustment of stock warrants 1,082 (5,954)
Premium deficiency reserve 3,128 (2,814)
Changes in assets and liabilities:    
Health plan receivable (30,540) (49,555)
Clinic fees, insurance, and other receivable 5,563 (376)
Prepaid expenses and other current assets 139 1,890
Other long-term assets (1,289) 0
Accounts payable, accrued expenses, and other current liabilities 1,924 1,163
Accrued payroll (3,086) (3,041)
Health plan settlements payable (6,730) (4,526)
Claims payable 7,321 37,364
Accrued interest 4,625 2,559
Operating lease liability (452) 3,555
Net cash used in operating activities (52,564) (73,088)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchases of property and equipment (1,652) (1,401)
Net cash used in investing activities (1,652) (1,401)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from long-term debt, net of original issuance discount 14,102 0
Proceeds from private placement offering, net of offering costs paid 87,329 0
Repayment of long-term debt 0 (2,446)
Payment of debt issuance costs (173) 0
Net cash provided by (used in) financing activities 101,258 (2,446)
Net change in cash and restricted cash 47,042 (76,935)
Cash and restricted cash, beginning of period 18,457 140,834
Cash and restricted cash, end of period $ 65,499 $ 63,899